Majd A. AbuAlrob

Dr. Majd A. AbuAlrob


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
BMBOULENOUAR MESRAOUA
BOULENOUAR MESRAOUA
BABassel Abou-Khalil
Bassel Abou-Khalil
BSBernhard Schuknecht
Bernhard Schuknecht
HHHassan Al Hail
Hassan Al Hail
MAMusab Ali
Musab Ali
AAAli Asadi-Pooya
Ali Asadi-Pooya
Epilepsy is a clinical diagnosis. In a patient suspected of epilepsy, the main contribution of routine EEG is to record interictal epileptiform discharges (IEDs) which include spikes, sharp waves, spike-and-wave discharges, sharp-and-wave discharges, and multiple spike-and-wave discharges. Studies show that the first routine EEG fails to record IEDs in approximately 47–50% of patients with epilepsy. When the clinical history strongly suggests epilepsy, but the first EEG fails to record IEDs, various measures can improve EEG performance, which is the subject of this review. Similarly, in cases of suspected epilepsy, magnetic resonance imaging (MRI) has become the imaging technique of choice to identify structural brain abnormalities. However, in a significant number of cases of clinically suspected epilepsy, MRI is interpreted as “normal” even when performed according to an epilepsy-specific protocol and when evaluated by a specialized MRI reader. In such cases, a comprehensive epilepsy-targeted MRI protocol is the key factor to identify, localize, and characterize an epileptogenic lesion. In this regard, the ILAE Neuroimaging Working Group recommends using the Harmonized Neuroimaging of Epilepsy Structural Sequences (HARNESS-MRI) protocol, among other additional imaging tools, to look for such a lesion; this will be also described in detail below.

30 April 2026 in Journal of Neuroimmunology
Verified
Journal Article
Open access
KZKhaled Zammar
Khaled Zammar
ASAbeer Safan
Abeer Safan
DADareen Jamal Abushalbak
Dareen Jamal Abushalbak
ADAdam Daromar
Adam Daromar
BCBeatriz Canibano
Beatriz Canibano
SHShahd Hamid
Shahd Hamid
Monoclonal antibodies have transformed the treatment of neuromyelitis optica spectrum disorder (NMOSD), yet their comparative efficacy by aquaporin-4 immunoglobulin G (AQP4-IgG) serostatus remains uncertain. We conducted a systematic review and meta-analysis to compare monoclonal antibody efficacy between AQP4-IgG seropositive and seronegative NMOSD patients. We searched PubMed/MEDLINE, Embase, and Cochrane CENTRAL from inception through January 2025 for studies comparing monoclonal antibody efficacy outcomes (rituximab, eculizumab, satralizumab, inebilizumab, tocilizumab, or ravulizumab) between seropositive and seronegative NMOSD patients. Primary outcomes included annualized relapse rate (ARR) and relapse events. Secondary outcomes included disability progression (Expanded Disability Status Scale [EDSS]) and infectious adverse events. Random-effects meta-analysis was performed. The protocol was registered in PROSPERO (CRD1049290). Thirteen studies (4 randomized controlled trials [RCTs], 9 observational) comprising 1284 patients (1010 seropositive; 274 seronegative) were included. Seropositive patients had significantly lower relapse risk (risk ratio [RR] = 0.66; 95% CI: 0.49-0.89; p = 0.007; I2 = 0%; 9 studies), indicating 34% greater efficacy in preventing relapses. An RCT-only subgroup analysis demonstrated a 59% relative risk reduction favoring seropositive patients (RR = 0.41; 95% CI: 0.25-0.69; p = 0.0008; I2 = 0%). No significant differences were observed for continuous ARR (standardized mean difference [SMD] = 0.23; p = 0.61; I2 = 94%), disability progression (SMD = 1.07; p = 0.32; I2 = 96%), or infectious adverse events (RR = 1.13; p = 0.61; I2 = 0%). Monoclonal antibodies demonstrate significantly greater efficacy in preventing relapses in AQP4-IgG seropositive compared with seronegative NMOSD patients. Serostatus should inform treatment selection and expectations. Comparable safety profiles support continued use in seronegative patients, though further research is needed to optimize therapeutic strategies for this population.